- COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
-
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
- -
-
Page/Page column 743
(2018/10/25)
-
- Compounds and methods for inhibiting phosphate transport
-
Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, A, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
- -
-
Page/Page column 234
(2016/05/02)
-
- SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1
-
Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
- -
-
Paragraph 00608
(2016/04/26)
-
- KINASE INHIBITORS
-
Compounds of formula (I) or a pharmaceutically acceptable salt thereof: formula (I) wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
- -
-
Page/Page column 209; 210
(2013/06/27)
-
- KINASE INHIBITORS
-
Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
- -
-
Paragraph 0830; 0831
(2013/06/27)
-
- COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
-
Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically ac
- -
-
Page/Page column 72
(2012/02/01)
-
- COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
-
Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically ac
- -
-
Page/Page column 45-46
(2012/02/01)
-
- COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
-
Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically ac
- -
-
Page/Page column 52
(2012/02/01)
-
- C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE
-
A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).
- -
-
Page/Page column 64
(2012/09/11)
-
- INHIBITORS OF ANTHRAX LETHAL FACTOR
-
Methods, compounds and compositions for preventing and treating anthrax infections by inhibiting Anthrax Lethal Factor (LF) activity.
- -
-
-
- RENIN INHIBITING N-(2-AMINO-2-OXOETHYL)BUTANEDIAMIDE DERIVATIVES
-
Disclosed herein are compounds of the formula:A--N(R. sup.1)C(O)CH 2 CHR 2 C(O)--B wherein A is R 3 R 4 NC(O)CH 2 wherein, for example, R 3 is hydrogen or alkyl and R 4 is hydrogen, alkyl or a substituted alkyl such as 2-(2-pyridinyl)ethyl, o
- -
-
-
- Asymmetric synthesis catalyzed by chiral ferrocenylphosphine transition metal complexes. 10 gold(I)-catalyzed asymmetric aldol reaction of isocyanoacetate
-
Optically active ferrocenylbisphosphine ligands containing 2-(dialkylamino)ethylamino group on the ferrocenylmethyl position have been prepared and used for the gold(I)-catalyzed asymmetric aldol reaction of isocyanoacetate with aldehydes. Six-membered ring amines, such as morpholino or piperidino group, at the terminal of the side chain were most stereoselective to give optically active trans-4- methoxycarbonyl-5-alkyl-2-oxazolines (up to 97% ee) with high enantio- and diastereoselectivity in a quantitative yield.
- Hayashi, Tamio,Sawamura, Masaya,Ito, Yoshihiko
-
p. 1999 - 2012
(2007/10/02)
-